Literature DB >> 23525860

Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study.

Christian Walter1, Christian Laux, Keyvan Sagheb.   

Abstract

OBJECTIVES: Most patients with bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) report a previous tooth extraction at the necrosis site before the diagnosis was made. At older ages, most teeth are extracted due to periodontal disease, which is per se another BP-ONJ trigger factor. The aim of this study was to evaluate the periodontal status of BP-ONJ patients using panoramic radiographs compared to a control.
MATERIALS AND METHODS: All patients treated for BP-ONJ up to January 1, 2010 comprised the study. The very first panoramic radiograph was analyzed. The number of remaining teeth and the radiographic bone loss from the cemento-enamel junction to the crestal bone were measured. For each patient, one control was analyzed (matching for gender and age).
RESULTS: One hundred twenty-nine BP-ONJ panoramic radiographs and 129 controls were analyzed (68 women, 61 men; 67.3 ± 9.7 years; osteoporosis [n = 11], breast cancer [n = 33], multiple myeloma [n = 61], prostate cancer [n = 24]). The average number of remaining teeth was 12.9 ± 8.4 for BP-ONJ and 16.4 ± 9.4 for the control (p = 0.02). The average radiographic bone loss was 5.5 ± 2.3 mm for BP-ONJ and 3.1 ± 1.1 mm for the control (p < 0.001); 96.6 % of BP-ONJ and 77.5 % had radiographic bone loss of more than 5 mm. Radiographic bone loss in the molar region was the highest for both groups (BP-ONJ 6.0 ± 2.3 mm; control 3.6 ± 1.4 mm).
CONCLUSION: Prevalence and severity of periodontal disease in patients with BP-ONJ is higher compared to healthy controls. CLINICAL RELEVANCE: Patients with periodontal disease might be at a higher risk of developing BP-ONJ; therefore, periodontal disease therapy in patients who are about to receive bisphosphonates should be undertaken.

Entities:  

Mesh:

Year:  2013        PMID: 23525860     DOI: 10.1007/s00784-013-0974-7

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  22 in total

1.  Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study.

Authors:  Daniela Carmagnola; Silvio Celestino; Silvio Abati
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2008-09-17

Review 2.  Periodontal diseases and tooth loss.

Authors:  R C Oliver; L J Brown
Journal:  Periodontol 2000       Date:  1993-06       Impact factor: 7.589

3.  The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

Authors:  Andreas M Pabst; Thomas Ziebart; Felix P Koch; Katherine Y Taylor; Bilal Al-Nawas; Christian Walter
Journal:  Clin Oral Investig       Date:  2011-01-12       Impact factor: 3.573

4.  Bacteria-reactive immune response may induce RANKL-expressing T cells in the mouse periapical bone loss lesion.

Authors:  Marcelo J B Silva; Mikihito Kajiya; Emad AlShwaimi; Hajime Sasaki; Jennifer Hong; Peter Ok; Taia M B Rezende; Tom C Pagonis; Robert R White; Bruce J Paster; Philip Stashenko; Toshihisa Kawai
Journal:  J Endod       Date:  2012-01-24       Impact factor: 4.171

5.  Radiographic manifestations of multiple myeloma in the mandible: a retrospective study of 77 patients.

Authors:  C Witt; A C Borges; K Klein; H J Neumann
Journal:  J Oral Maxillofac Surg       Date:  1997-05       Impact factor: 1.895

6.  Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction.

Authors:  Giorgia Saia; Stella Blandamura; Giordana Bettini; Anita Tronchet; Andrea Totola; Giorgio Bedogni; Giuseppe Ferronato; Pier Francesco Nocini; Alberto Bedogni
Journal:  J Oral Maxillofac Surg       Date:  2010-04       Impact factor: 1.895

7.  Use of cone-beam computerized tomography for evaluation of bisphosphonate-associated osteonecrosis of the jaws.

Authors:  Nathaniel S Treister; Bernard Friedland; Sook-Bin Woo
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-03-29

8.  Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.

Authors:  C Walter; A Pabst; T Ziebart; Mo Klein; B Al-Nawas
Journal:  Oral Dis       Date:  2010-08-27       Impact factor: 3.511

9.  Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.

Authors:  C Walter; M O Klein; A Pabst; B Al-Nawas; H Duschner; T Ziebart
Journal:  Clin Oral Investig       Date:  2009-03-18       Impact factor: 3.573

10.  Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

Authors:  Christian Walter; Bilal Al-Nawas; Knut A Grötz; Christian Thomas; Joachim W Thüroff; Viktoria Zinser; Heinold Gamm; Joachim Beck; Wilfried Wagner
Journal:  Eur Urol       Date:  2008-06-26       Impact factor: 20.096

View more
  8 in total

1.  Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation.

Authors:  Nadine Hagelauer; Thomas Ziebart; Andreas M Pabst; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-09-27       Impact factor: 3.573

2.  Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.

Authors:  A M Pabst; M Krüger; T Ziebart; C Jacobs; C Walter
Journal:  Clin Oral Investig       Date:  2015-01-16       Impact factor: 3.573

3.  Analysis of reasons for osteonecrosis of the jaws.

Authors:  Christian Walter; Keyvan Sagheb; Jennifer Bitzer; Roman Rahimi-Nedjat; Katherine Joyce Taylor
Journal:  Clin Oral Investig       Date:  2014-02-18       Impact factor: 3.573

4.  Associations between Systemic Markers of Bone Turnover or Bone Mineral Density and Anti-Resorptive Agent-Related Osteonecrosis of the Jaw in Patients Treated with Anti-Resorptive Agents.

Authors:  Kazuhito Tohashi; Motoki Nakabayashi; Isamu Kodani; Kazunori Kidani; Kazuo Ryoke
Journal:  Yonago Acta Med       Date:  2016-04-01       Impact factor: 1.641

5.  In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.

Authors:  Nadine Hagelauer; Andreas Max Pabst; Thomas Ziebart; Holger Ulbrich; Christian Walter
Journal:  Clin Oral Investig       Date:  2014-03-26       Impact factor: 3.573

Review 6.  Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review.

Authors:  Pongsapak Wongratwanich; Kiichi Shimabukuro; Masaru Konishi; Toshikazu Nagasaki; Masahiko Ohtsuka; Yoshikazu Suei; Takashi Nakamoto; Rinus G Verdonschot; Tomohiko Kanesaki; Pipop Sutthiprapaporn; Naoya Kakimoto
Journal:  Dentomaxillofac Radiol       Date:  2021-01-15       Impact factor: 3.525

Review 7.  Dental implants in patients treated with antiresorptive medication - a systematic literature review.

Authors:  Christian Walter; Bilal Al-Nawas; Tim Wolff; Eik Schiegnitz; Knut A Grötz
Journal:  Int J Implant Dent       Date:  2016-04-04

Review 8.  Imaging in Patients with Bisphosphonate-Associated Osteonecrosis of the Jaws (MRONJ).

Authors:  Britt-Isabelle Berg; Andreas A Mueller; Marcello Augello; Scott Berg; Claude Jaquiéry
Journal:  Dent J (Basel)       Date:  2016-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.